<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5668">
  <stage>Registered</stage>
  <submitdate>27/12/2013</submitdate>
  <approvaldate>27/12/2013</approvaldate>
  <nctid>NCT02024789</nctid>
  <trial_identification>
    <studytitle>A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)</studytitle>
    <scientifictitle>A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-001263-23</secondaryid>
    <secondaryid>BP27832</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Down Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Down's syndrome</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Placebo
Treatment: drugs - RG1662
Treatment: drugs - RG1662

Placebo Comparator: Placebo - 

Experimental: RG1662 120 mg bid - 

Experimental: RG1662 240 mg bid - 


Treatment: drugs: Placebo
Orally twice daily, 26 weeks

Treatment: drugs: RG1662
120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

Treatment: drugs: RG1662
240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cognition as assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) sub-tests</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Adaptive behavior as assessed by the Vineland Adaptive Behavior Scales-II (VABS-II) standard scores</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Clinical global impression as assessed by Clinician Rated Global Improvement (CGI-I) scale</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of abnormal ECG changes</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Abnormal ECG changes in adolescents as compared to baseline</outcome>
      <timepoint>from baseline to Week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>approximately 32 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of abnormal blood pressure</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>RG1662 plasma concentrations</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Individuals aged 12-30 years of age inclusive

          -  Clinical diagnosis of Down syndrome (trisomy 21) confirmed by chromosomal analysis
             (karyotyping)

          -  Males, or non-pregnant, non-lactating females. For females of childbearing potential,
             strict contraceptive prevention is required.

          -  Body-mass Index (BMI) 18-42 and 15-30 kg/m2 inclusive for adults and adolescents
             respectively

          -  Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool
             2 word classes task

          -  Subjects must have a parent, or other reliable caregiver who agrees to accompany the
             subject to all clinic visits, provide information about the subject as required by the
             protocol, and ensure compliance with the medication schedule

          -  Study participants must have sufficient language, vision and hearing to participate in
             study evaluations, as judged clinically by investigator</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with a current DSM 5 diagnosis of any primary psychiatric diagnosis
             (including ASD or MDD)

          -  Subjects with a history of infantile spasms, of West syndrome, Lennox-Gastaut
             syndrome, Early Infantile Epileptic Encephalopathy or any treatment-refractory
             epilepsy associated with cognitive or developmental regression, of severe head trauma
             or CNS infections (e.g. meningitis)

          -  Subjects with a known or suspected clinical seizure event of any type within 24 months
             prior to screening

          -  Clinically relevant ECG abnormalities at screening or baseline; QTcF above 450 ms;
             personal or family history (first degree relatives) of congenital long QT syndrome

          -  Inadequate renal or hepatic function</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>5/05/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>173</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>4/05/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Caba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma de Bs As</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St Etienne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Sardegna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Jalisco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Aguascalientes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Queretaro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Girona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>La Coruña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dartford, Kent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Doncaster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Redruth</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study
      will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome.
      Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally
      twice daily for 26 weeks.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02024789</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>